Ide-cel
1 product
12 abstracts
Abstract
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.Org: Hospital Clinico Universitario de Salamanca,
Abstract
BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, H. Lee Moffitt Cancer Center and Research Institute, University of Pennsylvania, Hospital of the University of Pennsylvania, University of California, San Francisco,
Abstract
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.Org: Bristol Myers Squibb, Mayo Clinic, Lille University Hospital, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.Org: Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, UT Southwestern Medical Center, Medical University of South Carolina Hollings Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Stanford University School of Medicine,
Abstract
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).Org: Bristol Myers Squibb, Princeton, NJ, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center,
Abstract
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).Org: MD Anderson Cancer Center, Bristol Myers Squibb, Evidera, Inc, Seràgnoli Institute of Hematology, Winship Cancer Center of Emory University,
Abstract
Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).Org: Bristol Myers Squibb, Mount Sinai Medical Center, Dana-Farber Cancer Institute,
Abstract
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Department of Radiology, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Mayo Clinic, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).Org: Bristol Myers Squibb, Princeton Health, Lille University Hospital, Lille, France, Mayo Clinic,
Abstract
Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.Org: Massachusetts College of Pharmacy and Health Sciences, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology,
Abstract
Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Emory University School of Medicine, Biostatistics Shared Resource, Emory University, Atlanta, GA, USA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Product
Ide-cel